Pure Biologics achieves key milestone with successful completion of Phase 0 study for PBA-0405 in cancer treatment

Pure Biologics today announced the successful completion of its Phase 0 clinical study for the novel cancer therapy, PBA-0405.

9 February

2021

European patent for modified aptamers (PB012 PureApta)

The European Patent Office issued a decision on granting a European patent for PureApta elements.

28 January

2021

Klaus, T., Deshmukh, S. pH-responsive antibodies for therapeutic applications. J Biomed Sci 28, 11 (2021)

12 January

2021

The National Center for Research and Development placed the project on the list of beneficiaries' successes.

8 January

2021

The research is carried out by Timeline Bioresearch, experienced in immuno-oncology and intestinal cancer models.

16 December

2020

News on the debut of Pure Biologics on the WSE Main Market in key business and industry media.

18 December

2023

23 November

2023

9 October

2020

17 June

2020

10 April

2020